221 related articles for article (PubMed ID: 36951119)
1. The impact of immunosuppressive agents on immune checkpoint inhibitor efficacy in patients with advanced melanoma: A real-world, multicenter, retrospective study.
Lev-Ari S; Serzan M; Wu T; Ip A; Pascual L; Sinclaire B; Adams S; Marafelias M; Ayyagari L; Gill SK; Ma B; Zaemes JP; Della Pia A; Alaoui A; Madhavan S; Belouali A; Pecora A; Ahn J; Atkins MB; Shah NJ
Cancer; 2023 Jun; 129(12):1885-1894. PubMed ID: 36951119
[TBL] [Abstract][Full Text] [Related]
2. Clinical characteristics of gastrointestinal immune-related adverse events of immune checkpoint inhibitors and their association with survival.
Yamada K; Sawada T; Nakamura M; Yamamura T; Maeda K; Ishikawa E; Iida T; Mizutani Y; Kakushima N; Ishikawa T; Furukawa K; Ohno E; Honda T; Kawashima H; Ishigami M; Furune S; Hase T; Yokota K; Maeda O; Hashimoto N; Akiyama M; Ando Y; Fujishiro M
World J Gastroenterol; 2021 Nov; 27(41):7190-7206. PubMed ID: 34887637
[TBL] [Abstract][Full Text] [Related]
3. Association of Immune-Related Adverse Event Management With Survival in Patients With Advanced Melanoma.
van Not OJ; Verheijden RJ; van den Eertwegh AJM; Haanen JBAG; Aarts MJB; van den Berkmortel FWPJ; Blank CU; Boers-Sonderen MJ; de Groot JB; Hospers GAP; Kamphuis AM; Kapiteijn E; May AM; de Meza MM; Piersma D; van Rijn R; Stevense-den Boer MA; van der Veldt AAM; Vreugdenhil G; Blokx WAM; Wouters MJM; Suijkerbuijk KPM
JAMA Oncol; 2022 Dec; 8(12):1794-1801. PubMed ID: 36301521
[TBL] [Abstract][Full Text] [Related]
4. Survival Among Veterans Receiving Steroids for Immune-Related Adverse Events After Immune Checkpoint Inhibitor Therapy.
Van Buren I; Madison C; Kohn A; Berry E; Kulkarni RP; Thompson RF
JAMA Netw Open; 2023 Oct; 6(10):e2340695. PubMed ID: 37906189
[TBL] [Abstract][Full Text] [Related]
5. Anti-PD1-Induced Immune-Related Adverse Events and Survival Outcomes in Advanced Melanoma.
Suo A; Chan Y; Beaulieu C; Kong S; Cheung WY; Monzon JG; Smylie M; Walker J; Morris D; Cheng T
Oncologist; 2020 May; 25(5):438-446. PubMed ID: 32048768
[TBL] [Abstract][Full Text] [Related]
6. The association between immune-related adverse events and survival outcomes in Asian patients with advanced melanoma receiving anti-PD-1 antibodies.
Wu CE; Yang CK; Peng MT; Huang PW; Chang CF; Yeh KY; Chen CB; Wang CL; Hsu CW; Chen IW; Lin CT; Ueng SH; Lin G; Lin YF; Cheng CY; Chang JW
BMC Cancer; 2020 Oct; 20(1):1018. PubMed ID: 33087090
[TBL] [Abstract][Full Text] [Related]
7. Incidence and Outcome of Neurologic Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors in Patients With Melanoma.
Pepys J; Stoff R; Ramon-Gonen R; Ben-Betzalel G; Grynberg S; Frommer RS; Schachter J; Asher N; Taliansky A; Nikitin V; Dori A; Shelly S
Neurology; 2023 Dec; 101(24):e2472-e2482. PubMed ID: 37652699
[TBL] [Abstract][Full Text] [Related]
8. Association between immune-related adverse events and efficacy of PD-1 inhibitors in Chinese patients with advanced melanoma.
Zhao JJ; Wen XZ; Ding Y; Li DD; Zhu BY; Li JJ; Weng DS; Zhang X; Zhang XS
Aging (Albany NY); 2020 Jun; 12(11):10663-10675. PubMed ID: 32516130
[TBL] [Abstract][Full Text] [Related]
9. Safety and Efficacy of Checkpoint Inhibition in Patients With Melanoma and Preexisting Autoimmune Disease : A Cohort Study.
van der Kooij MK; Suijkerbuijk KPM; Aarts MJB; van den Berkmortel FWPJ; Blank CU; Boers-Sonderen MJ; van Breeschoten J; van den Eertwegh AJM; de Groot JWB; Haanen JBAG; Hospers GAP; Piersma D; van Rijn RS; Ten Tije AJ; van der Veldt AAM; Vreugdenhil G; van Zeijl MCT; Wouters MWJM; Dekkers OM; Kapiteijn E
Ann Intern Med; 2021 May; 174(5):641-648. PubMed ID: 33587686
[TBL] [Abstract][Full Text] [Related]
10. Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non-Small Cell Lung Cancer.
Shankar B; Zhang J; Naqash AR; Forde PM; Feliciano JL; Marrone KA; Ettinger DS; Hann CL; Brahmer JR; Ricciuti B; Owen D; Toi Y; Walker P; Otterson GA; Patel SH; Sugawara S; Naidoo J
JAMA Oncol; 2020 Dec; 6(12):1952-1956. PubMed ID: 33119034
[TBL] [Abstract][Full Text] [Related]
11. Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors.
Ma VT; Su CT; Hu M; Taylor JMG; Daignault-Newton S; Kellezi O; Dahl MN; Shah MA; Erickson S; Lora J; Hamasha R; Ali A; Yancey S; Kiros L; Balicki HM; Winfield DC; Green MD; Alva AS
Urol Oncol; 2021 Jul; 39(7):437.e1-437.e9. PubMed ID: 33495117
[TBL] [Abstract][Full Text] [Related]
12. Prediction of severe immune-related adverse events requiring hospital admission in patients on immune checkpoint inhibitors: study of a population level insurance claims database from the USA.
Kalinich M; Murphy W; Wongvibulsin S; Pahalyants V; Yu KH; Lu C; Wang F; Zubiri L; Naranbhai V; Gusev A; Kwatra SG; Reynolds KL; Semenov YR
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33789879
[TBL] [Abstract][Full Text] [Related]
13. Association of Immune-Related Adverse Events, Hospitalization, and Therapy Resumption With Survival Among Patients With Metastatic Melanoma Receiving Single-Agent or Combination Immunotherapy.
Watson AS; Goutam S; Stukalin I; Ewanchuk BW; Sander M; Meyers DE; Pabani A; Cheung WY; Heng DYC; Cheng T; Monzon JG; Navani V
JAMA Netw Open; 2022 Dec; 5(12):e2245596. PubMed ID: 36480204
[TBL] [Abstract][Full Text] [Related]
14. Prevalence of immune-related adverse events and anti-tumor efficacy following immune checkpoint inhibitor therapy in Japanese patients with various solid tumors.
Yoshikawa Y; Imamura M; Yamauchi M; Hayes CN; Aikata H; Okamoto W; Miyata Y; Okada M; Hattori N; Sugiyama K; Yoshioka Y; Toratani S; Takechi M; Ichinohe T; Ueda T; Takeno S; Kobayashi T; Ohdan H; Teishima J; Hide M; Nagata Y; Kudo Y; Iida K; Chayama K
BMC Cancer; 2022 Nov; 22(1):1232. PubMed ID: 36447159
[TBL] [Abstract][Full Text] [Related]
15. Analysis of the association between prospectively collected immune-related adverse events and survival in patients with solid tumor treated with immune-checkpoint blockers, taking into account immortal-time bias.
Kfoury M; Najean M; Lappara A; Voisin AL; Champiat S; Michot JM; Laghouati S; Robert C; Besse B; Soria JC; Lambotte O; Massard C; Marabelle A; Texier M
Cancer Treat Rev; 2022 Nov; 110():102452. PubMed ID: 35998515
[TBL] [Abstract][Full Text] [Related]
16. Immune-Related Adverse Events in PD-1 Treated Melanoma and Impact Upon Anti-Tumor Efficacy: A Real World Analysis.
Bastacky ML; Wang H; Fortman D; Rahman Z; Mascara GP; Brenner T; Najjar YG; Luke JJ; Kirkwood JM; Zarour HM; Davar D
Front Oncol; 2021; 11():749064. PubMed ID: 34900695
[TBL] [Abstract][Full Text] [Related]
17. Infectious complications in patients treated with immune checkpoint inhibitors.
Karam JD; Noel N; Voisin AL; Lanoy E; Michot JM; Lambotte O
Eur J Cancer; 2020 Dec; 141():137-142. PubMed ID: 33137589
[TBL] [Abstract][Full Text] [Related]
18. Analysis of Human Leukocyte Antigen DR Alleles, Immune-Related Adverse Events, and Survival Associated With Immune Checkpoint Inhibitor Use Among Patients With Advanced Malignant Melanoma.
Akturk HK; Couts KL; Baschal EE; Karakus KE; Van Gulick RJ; Turner JA; Pyle L; Robinson WA; Michels AW
JAMA Netw Open; 2022 Dec; 5(12):e2246400. PubMed ID: 36512357
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the modified immune prognostic index to prognosticate outcomes in metastatic uveal melanoma patients treated with immune checkpoint inhibitors.
Sander MS; Stukalin I; Vallerand IA; Goutam S; Ewanchuk BW; Meyers DE; Pabani A; Morris DG; Heng DYC; Cheng T
Cancer Med; 2021 Apr; 10(8):2618-2626. PubMed ID: 33724676
[TBL] [Abstract][Full Text] [Related]
20. Clinical Outcomes and Toxic Effects of Single-Agent Immune Checkpoint Inhibitors Among Patients Aged 80 Years or Older With Cancer: A Multicenter International Cohort Study.
Nebhan CA; Cortellini A; Ma W; Ganta T; Song H; Ye F; Irlmeier R; Debnath N; Saeed A; Radford M; Alahmadi A; Diamond A; Hoimes C; Ramaiya N; Presley CJ; Owen DH; Abou Alaiwi S; Nassar A; Ricciuti B; Lamberti G; Bersanelli M; Casartelli C; Buti S; Marchetti P; Giusti R; Filetti M; Vanella V; Mallardo D; Macherla S; Sussman TA; Botticelli A; Galetta D; Catino A; Pizzutilo P; Genova C; Dal Bello MG; Kalofonou F; Daniels E; Ascierto PA; Pinato DJ; Choueiri TK; Johnson DB; Marron TU; Wang Y; Naqash AR
JAMA Oncol; 2021 Dec; 7(12):1856-1861. PubMed ID: 34734989
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
